[HTML][HTML] COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management
P Li, Y Liu, Z Cheng, X Yu, Y Li - Biomedicine & Pharmacotherapy, 2022 - Elsevier
Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2), has become a global epidemic and poses a major …
syndrome coronavirus-2 (SARS-CoV-2), has become a global epidemic and poses a major …
Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study
J Wang, Q Zhang, J Ai, D Liu, C Liu, H Xiang… - Hepatology …, 2022 - Springer
Background Data on safety and immunogenicity of coronavirus disease 2019 (COVID-19)
vaccination in patients with compensated (C-cirrhosis) and decompensated cirrhosis (D …
vaccination in patients with compensated (C-cirrhosis) and decompensated cirrhosis (D …
[HTML][HTML] COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis
Methods We collected data via three databases from inception to February 16, 2022, and
reported pooled seroconversion rate, T cell response and safety data after two vaccine …
reported pooled seroconversion rate, T cell response and safety data after two vaccine …
Autoimmune hepatitis after COVID-19 vaccination
H Zheng, T Zhang, Y Xu, X Lu, X Sang - Frontiers in Immunology, 2022 - frontiersin.org
Vaccination is one of the most vigorous ways to intervene in the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) pandemic. Cases of autoimmune hepatitis (AIH) …
syndrome coronavirus 2 (SARS-CoV-2) pandemic. Cases of autoimmune hepatitis (AIH) …
[HTML][HTML] Early diagnosis and prevention of infections in cirrhosis
Strategies to prevent infection and improve outcomes in patients with cirrhosis. HAV,
hepatitis A virus; HBV, hepatitis B virus; COVID-19, novel coronavirus disease 2019; NSBB …
hepatitis A virus; HBV, hepatitis B virus; COVID-19, novel coronavirus disease 2019; NSBB …
Patients with liver cirrhosis show high immunogenicity upon COVID-19 vaccination but develop premature deterioration of antibody titers
K Willuweit, A Frey, M Passenberg, J Korth, N Saka… - Vaccines, 2022 - mdpi.com
SARS-CoV-2 infection is known to lead to severe morbidity and mortality in patients with
liver cirrhosis. For this reason, vaccination of these patients against COVID-19 is widely …
liver cirrhosis. For this reason, vaccination of these patients against COVID-19 is widely …
[HTML][HTML] COVID-19 and liver injury: An ongoing challenge
I Papagiouvanni, SC Kotoulas, A Pataka… - World Journal of …, 2023 - ncbi.nlm.nih.gov
The new coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was
identified in December 2019, in Wuhan, China. The virus was rapidly spread worldwide …
identified in December 2019, in Wuhan, China. The virus was rapidly spread worldwide …
Vaccination in chronic liver disease: an update
JJ Alukal, HA Naqvi, PJ Thuluvath - Journal of Clinical and Experimental …, 2022 - Elsevier
Patients with chronic liver disease (CLD) with or without cirrhosis remain at risk of
developing hepatic decompensation when infected with viral or bacterial pathogens. The …
developing hepatic decompensation when infected with viral or bacterial pathogens. The …
Antibody responses after SARS-CoV-2 vaccination in patients with liver diseases
AD Bakasis, K Bitzogli, D Mouziouras, A Pouliakis… - Viruses, 2022 - mdpi.com
The novel mRNA-based vaccines against SARS-CoV-2 display encouraging safety and
efficacy profiles. However, there is a paucity of data regarding their immunogenicity and …
efficacy profiles. However, there is a paucity of data regarding their immunogenicity and …